Table of Contents

01. NICE's response to comments on the Appraisal Consultation Document (ACD)

02. Consultee comments on the ACD - Otsuka Pharmaceuticals

03. New evidence - Otsuka Pharmaceuticals

04. Consultee comments on the ACD - Polycystic Kidney Disease (PKD) Charity

05. Patient expert comments on the ACD - Goren

06. Clinical expert comments on the ACD - Ong

07. Patient expert comments on the ACD - Williams

08. Personal statement from clinical expert - Sayer

09. Public comments on the ACD received via the NICE website

10. Company response to NICE clarification request - Otsuka Pharmaceuticals

11. Evidence Review Group critique of company's new evidence - KSR Ltd